The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Werewolf Therapeutics to present WTX-124, WTX-330 at SITC 2026

Oct 30, 2026 12:30 (2h ago)

Verifying

Werewolf Therapeutics will present WTX-124 and WTX-330 research at SITC 2026.
November 4-8, 2026, marks the Society for Immunotherapy of Cancer meeting in Phoenix.
WTX-124 and WTX-330 are clinical-stage IL-2 and IL-12 candidates.